Create Medicines raised $122 million to advance in vivo CAR-T programs spanning autoimmune disease and oncology, betting on one-day manufacturing inside the patient rather than traditional ex vivo cell processing. The Series B was co-led by Arch Venture Partners, Newpath Partners, and Hatteras Venture Partners, with additional participation from Alexandria Venture Investments and others. The startup said it has dosed more than 50 patients and pointed to ongoing clinical development, including its Phase 1/2 trial for MT-304 targeting HER2 in breast cancer and other HER2-positive solid tumors. It also positioned additional programs directed at CD19 and BCMA for autoimmune indications. In parallel, a separate report highlighted that Winship Cancer Institute clinicians administered the first investigational in vivo CAR-T dose in the US for relapsed or refractory multiple myeloma, emphasizing how clinical translation for in vivo approaches continues to expand across centers.